Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ros Eeles

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Plos Genetics|November 10, 2010
Common genetic variants and modification of penetrance of BRCA2-associated breast cancerMia M Gaudet, Tomas Kirchhoff, Todd Green, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
European Urology|December 9, 2022
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
Journal of the National Cancer Institute|December 21, 2010
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriersSusan J Ramus, Christiana Kartsonaki, Simon A Gayther, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
Plos One|July 28, 2016
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation CarriersElena Vigorito, Karoline B Kuchenbaecker, Jonathan Beesley, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Breast Cancer Research : BCR|February 10, 2016
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.
Journal of the National Cancer Institute|July 28, 2021
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk ScoresDaniel R Barnes, Valentina Silvestri, Goska Leslie, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Plos Genetics|November 10, 2010
Common genetic variants and modification of penetrance of BRCA2-associated breast cancerMia M Gaudet, Tomas Kirchhoff, Todd Green, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
European Urology|December 9, 2022
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
Journal of the National Cancer Institute|December 21, 2010
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriersSusan J Ramus, Christiana Kartsonaki, Simon A Gayther, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
Plos One|July 28, 2016
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation CarriersElena Vigorito, Karoline B Kuchenbaecker, Jonathan Beesley, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Breast Cancer Research : BCR|February 10, 2016
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.
Journal of the National Cancer Institute|July 28, 2021
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk ScoresDaniel R Barnes, Valentina Silvestri, Goska Leslie, et al.
Pageof 8